<html><head></head><body><h1>Crotalidae Immune F(ab′)2 (Equine)</h1><p class="drug-subtitle"><b>Class:</b> Antitoxins and Immune Globulins<br/>
<b>VA Class:</b> IM300<br/>
<b>Brands:</b> Anavip</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Antivenin (antivenom); equine IgG F(ab′)<sub>2</sub> fragments capable of binding and neutralizing venom toxins of North American rattlesnakes (pit vipers).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Crotalidae Immune F(ab′)2 (Equine)</h2><h3>North American Rattlesnake Snakebite Envenomation</h3><p>Treatment of envenomation following snakebites involving North American rattlesnakes (Crotalinae, crotalines, pit vipers; formerly known as Crotalidae or crotalids).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Designated an orphan drug by FDA for this use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Crotalinae subfamily of venomous snakes includes rattlesnakes, copperheads, and cottonmouths or water moccasins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been effective in management of envenomation involving various crotaline, including <i>Crotalus</i>, <i>Sistrurus</i>, and <i>Agkistrodon</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consultation with experts experienced in treating snakebites (e.g., regional certified poison control center at 800-222-1222) recommended to guide treatment decisions regarding individual patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Crotalidae Immune F(ab′)2 (Equine) Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>Initiate treatment as soon as possible after rattlesnake bite in patients who develop clinically important signs of envenomation (e.g., local injury, coagulation abnormality, systemic signs of envenomation).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Prior to and during treatment, assess CBCs, serum chemistries, and coagulation parameters (e.g., PT, aPTT, serum fibrinogen concentration) to evaluate response to the antivenin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Monitor closely during and for at least 1 hour after IV infusion of the antivenin to assess for allergic reactions and confirm that local signs of envenomation are not progressing, systemic symptoms of envenomation have resolved, and coagulation abnormalities have normalized or are trending towards normalization.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Initiate treatment as soon as possible after rattlesnake bite in patients who develop clinically important signs of envenomation (e.g., local injury, coagulation abnormality, systemic signs of envenomation).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prior to and during treatment, assess CBCs, serum chemistries, and coagulation parameters (e.g., PT, aPTT, serum fibrinogen concentration) to evaluate response to the antivenin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor closely during and for at least 1 hour after IV infusion of the antivenin to assess for allergic reactions and confirm that local signs of envenomation are not progressing, systemic symptoms of envenomation have resolved, and coagulation abnormalities have normalized or are trending towards normalization.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>Administer by IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Must be reconstituted and diluted prior to administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reconstitute appropriate number of vials of lyophilized Crotalidae immune F(ab′)<sub>2</sub> (equine) by adding 10 mL of 0.9% sodium chloride to each vial; mix using continuous gentle swirling (usually dissolves within 1 minute).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Reconstituted solution should be clear to yellow/green and opalescent;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; do not use if discolored or turbid.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immediately after reconstitution, combine contents of appropriate number of reconstituted vials and dilute total dose (total combined reconstituted vials) to a total volume of 250 mL using 0.9% sodium chloride.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May need to adjust volume of dilution fluid for infants or very small children.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use reconstituted and diluted antivenin within 4 hours after reconstitution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Stability.)</p><p>Discard partially used reconstituted vials or unused diluted antivenin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer by IV infusion over 60 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Start initial IV infusion using reduced rate of 25–50 mL/hour for first 10 minutes; observe patient closely for sensitivity reactions (including anaphylaxis).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If reduced rate well tolerated, give remaining initial infusion at rate of 250 mL/hour.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If sensitivity reaction occurs, immediately discontinue IV infusion and reassess risks and benefits before continuing treatment with the antivenin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Sensitivity Reactions under Cautions.)</p><h3>Dosage</h3><p>Dosage expressed in terms of the number of vials.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Base initial dose (number of vials), need for additional initial doses to achieve envenomation control, and number of subsequent doses required for maintenance to sustain envenomation control on individual patient response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Age-related dosage adjustments not indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, 10 vials.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor closely for at least 1 hour after completion of infusion for allergic reaction and to determine if initial envenomation control achieved (i.e., local manifestations not progressing, systemic symptoms resolved, and coagulation abnormalities normalized or trending towards normalization).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If initial envenomation control not achieved, give additional 10-vial doses every 60 minutes as needed until envenomation controlled.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>After initial envenomation control established, monitor closely for recurrent coagulopathy for at least 18 hours in a healthcare setting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If coagulation abnormalities reoccur, give additional 4-vial doses as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, 10 vials.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor closely for at least 1 hour after completion of infusion for allergic reaction and to determine if initial envenomation control achieved (i.e., local manifestations not progressing, systemic symptoms resolved, and coagulation abnormalities normalized or trending towards normalization).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If initial envenomation control not achieved, give additional 10-vial doses every 60 minutes as needed until envenomation controlled.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>After initial envenomation control established, monitor closely for recurrent coagulopathy for at least 18 hours in a healthcare setting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If coagulation abnormalities reoccur, give additional 4-vial doses as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Maximum dosage not known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum dosage not known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>No special population dosage recommendations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Crotalidae Immune F(ab′)2 (Equine)</h2><h3>Contraindications</h3><ul>
<li>
<p>Manufacturer states none.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Manufacturer states none.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Severe hypersensitivity reactions, including anaphylaxis, may occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients with history of sensitivity to equine protein are at increased risk for anaphylactic reactions to Crotalidae immune F(ab′)<sub>2</sub> (equine).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor closely for signs and symptoms of acute hypersensitivity (e.g., urticaria, rash, bronchospasm with wheezing or cough, hypotension) during IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If hypersensitivity reaction occurs, immediately discontinue IV infusion and initiate appropriate emergency medical care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Carefully weigh potential risks and benefits of restarting Crotalidae immune F(ab′)<sub>2</sub> (equine) infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Delayed hypersensitivity or serum sickness reactions may occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usually manifest as fever, rash, urticaria, pruritus, myalgia, arthralgia, and lymphadenopathy;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; may occur 7–21 days after antivenin treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor for signs and symptoms of delayed allergic reactions or serum sickness.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If such reactions suspected, administer appropriate medical care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Coagulopathic effects, such as thrombocytopenia (platelet counts &lt;150,000/mm<sup>3</sup>), hypofibrinogenemia (fibrinogen concentrations &lt;150 mg/dL), and prolonged PT and PTT, are a complication in many snakebite victims (especially those with severe envenomation).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recurrent coagulopathy, characterized by thrombocytopenia, hypofibrinogenemia, and prolonged PT, can occur after successful initial control of envenomation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; There is some evidence that recurrent coagulopathy may occur less frequently in patients treated with Crotalidae immune F(ab′)<sub>2</sub> (equine) than in those treated with Crotalidae polyvalent immune Fab (ovine);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; may be related in part to pharmacokinetics of Crotalidae immune F(ab′)<sub>2</sub> (equine).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor for signs and symptoms of recurrent coagulopathy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manufacturer recommends that, after initial control of envenomation achieved with Crotalidae immune F(ab′)<sub>2</sub> (equine), monitor closely for reoccurrence of coagulation abnormalities for at least 18 hours in a healthcare setting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.) Some clinicians suggest that follow-up in patients treated with antivenin should include platelet counts, fibrinogen concentrations, hemoglobin, and PT at 2–3 days and 5–7 days after antivenin administration and as clinically indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prepared from equine plasma;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; potentially may transmit infectious agents (e.g., viruses).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Several steps in manufacturing process (e.g., pepsin digestion, ammonium sulfate precipitation/heat treatment, nanofiltration) reduce risk of transmission of viruses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Contains trace amounts of cresol (&lt;0.058 mg per vial) from manufacturing process.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Localized reactions and generalized myalgia reported when cresol used as an injectable excipient.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use during pregnancy only when clearly needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether Crotalidae immune F(ab′)<sub>2</sub> (equine) can cause fetal harm if administered to a pregnant woman or affect fertility.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; No animal reproduction studies performed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in nursing women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Efficacy and safety in pediatric patients comparable to that in adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In clinical trials, 24% of patients were children 2–16 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Age-related dosage adjustments not indicated since venom dose following snakebite is expected to be similar in children and adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, fluid volume used to dilute the antivenin may need to be adjusted in infants or small children.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Reconstitution and Dilution under Dosage and Administration.)</p><p>Efficacy in geriatric patients comparable to that in overall patient population.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In clinical trials, &gt;9% of patients were &gt;65 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Pruritus, nausea, rash, arthralgia, myalgia, peripheral edema, headache, extremity pain, vomiting, pyrexia, blister, erythema, chills, anxiety, insomnia, dehydration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Crotalidae Immune F(ab′)2 (Equine)</h2><p>No formal drug interaction studies.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Crotalidae Immune F(ab′)2 (Equine) Pharmacokinetics</h2><h3>Elimination</h3><p>Mean elimination half-life following single IV dose: Approximately 5.5 days in healthy (nonenvenomed) adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>Lyophilized powder: Room temperature (up to 25°C); may briefly expose to temperatures up to 40°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reconstituted and diluted solution: Use within 4 hours after reconstitution;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; discard partially used reconstituted vials and unused diluted solutions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Sodium chloride 0.9%</p><h2>Actions</h2><ul>
<li>
<p>Crotalidae immune F(ab′)<sub>2</sub> (equine) is a polyvalent antivenin (antivenom) preparation of venom-specific F(ab′)<sub>2</sub> fragments of equine IgG that bind and neutralize venom toxins of Crotalinae (rattlesnakes; genera <i>Crotalus</i> and <i>Sistrurus</i>) native to North America.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Following IV administration, the F(ab′)<sub>2</sub> fragments in Crotalidae immune F(ab′)<sub>2</sub> (equine) bind to venom components, facilitating redistribution of venom away from target tissues and elimination from the body.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Manufactured from plasma of horses immunized with venom of <i>Bothrops asper</i> and <i>Crotalus durissus</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Antivenin obtained by pepsin digestion of equine plasma to remove the F<sub>c</sub> portion of the equine IgG, followed by fractionation and purification to isolate the venom-specific F(ab′)<sub>2</sub> fragments.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; The antivenin is stabilized with sodium chloride, sucrose, and glycine; may contain trace amounts of pepsin, cresol, borates, and sulfates from the manufacturing process.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Standardized by ability to neutralize <i>B. asper</i> and <i>C. durissus</i> venom in mice (mouse LD<sub>50</sub> neutralizing units).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Crotalidae immune F(ab′)<sub>2</sub> (equine) is a polyvalent antivenin (antivenom) preparation of venom-specific F(ab′)<sub>2</sub> fragments of equine IgG that bind and neutralize venom toxins of Crotalinae (rattlesnakes; genera <i>Crotalus</i> and <i>Sistrurus</i>) native to North America.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IV administration, the F(ab′)<sub>2</sub> fragments in Crotalidae immune F(ab′)<sub>2</sub> (equine) bind to venom components, facilitating redistribution of venom away from target tissues and elimination from the body.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufactured from plasma of horses immunized with venom of <i>Bothrops asper</i> and <i>Crotalus durissus</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Antivenin obtained by pepsin digestion of equine plasma to remove the F<sub>c</sub> portion of the equine IgG, followed by fractionation and purification to isolate the venom-specific F(ab′)<sub>2</sub> fragments.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; The antivenin is stabilized with sodium chloride, sucrose, and glycine; may contain trace amounts of pepsin, cresol, borates, and sulfates from the manufacturing process.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Standardized by ability to neutralize <i>B. asper</i> and <i>C. durissus</i> venom in mice (mouse LD<sub>50</sub> neutralizing units).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of immediately contacting a clinician if any unusual bruising or bleeding (e.g., nosebleeds, excessive bleeding after brushing teeth, blood in stools or urine, excessive menstrual bleeding, petechiae, excessive bruising or persistent oozing from superficial injuries) occurs after hospital discharge.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of immediately contacting clinician or seeking emergency treatment if manifestations of a hypersensitivity reaction or anaphylaxis (e.g., urticaria, rash, tightness of the chest, wheezing, hypotension) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of immediately contacting clinician if manifestations of delayed allergic reactions or serum sickness (e.g., rash, pruritus, urticaria, myalgia, arthralgia, fever) occur after hospital discharge.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are pregnant or breast-feeding.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of immediately contacting a clinician if any unusual bruising or bleeding (e.g., nosebleeds, excessive bleeding after brushing teeth, blood in stools or urine, excessive menstrual bleeding, petechiae, excessive bruising or persistent oozing from superficial injuries) occurs after hospital discharge.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of immediately contacting clinician or seeking emergency treatment if manifestations of a hypersensitivity reaction or anaphylaxis (e.g., urticaria, rash, tightness of the chest, wheezing, hypotension) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of immediately contacting clinician if manifestations of delayed allergic reactions or serum sickness (e.g., rash, pruritus, urticaria, myalgia, arthralgia, fever) occur after hospital discharge.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are pregnant or breast-feeding.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>FDA has extended the expiration date on all lots of Crotalidae immune F(ab′)<sub>2</sub> (equine) from 24 months to 36 months (based on an evaluation of stability data).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Anavip<sup></sup> lot B-8G-33 (labeled with an expiration date of July 31, 2020) now has an expiration date of July 31, 2021; lot B-9B-33 (labeled with an expiration date of February 28, 2021) now has an expiration date of February 28, 2022; and lot B-9E-35 (labeled with an expiration date of June 30, 2021) now has an expiration date of June 30, 2022.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; These products may be retained until their new expiration dates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>For injection, for IV infusion</p><p>≥780 mouse LD<sub>50</sub> neutralizing units of <i>Bothrops asper</i> antivenin (equine) and ≥790 mouse LD<sub>50</sub> neutralizing units of <i>Crotalus durissus</i> antivenin (equine) per vial</p><p>Anavip<sup></sup></p><p>Rare Disease Therapeutics</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions April 27, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><h2>References</h2><p>1. Rare Disease Therapeutics. Anavip<sup></sup> (Crotalidae Immune F(ab′)<sub>2</sub> [Equine]) for injection prescribing information. Franklin, TN; 2019 Jun.</p><p>2. Boyer LV, Chase PB, Degan JA et al. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab')2 antivenoms. <i>Toxicon</i>. 2013; 74:101-8. http://www.ncbi.nlm.nih.gov/pubmed/23948058?dopt=AbstractPlus</p><p>3. Bush SP, Ruha AM, Seifert SA et al. Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. <i>Clin Toxicol (Phila)</i>. 2015; 53:37-45. http://www.ncbi.nlm.nih.gov/pubmed/25361165?dopt=AbstractPlus</p><p>4. Food and Drug Administration. FDA Application: Search Orphan Drug Designations and Approvals. Silver Spring, MD. From FDA website. Accessed 2019 Jul 18. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=177503</p><p>5. Gold BS, Dart RC, Barish RA. Bites of venomous snakes. <i>N Engl J Med</i>. 2002; 347:347-56. http://www.ncbi.nlm.nih.gov/pubmed/12151473?dopt=AbstractPlus</p><p>6. Lavonas EJ, Ruha AM, Banner W et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. <i>BMC Emerg Med</i>. 2011; 11:2. http://www.ncbi.nlm.nih.gov/pubmed/21291549?dopt=AbstractPlus</p><p>7. Ruha AM, Kleinschmidt KC, Greene S et al. The Epidemiology, Clinical Course, and Management of Snakebites in the North American Snakebite Registry. <i>J Med Toxicol</i>. 2017; 13:309-320. http://www.ncbi.nlm.nih.gov/pubmed/28975491?dopt=AbstractPlus</p><p>9. Cocchio C, Johnson J, Clifton S. Review of North American pit viper antivenoms. <i>Am J Health Syst Pharm</i>. 2020; 77:175-187. http://www.ncbi.nlm.nih.gov/pubmed/31974558?dopt=AbstractPlus</p><p>10. Food and Drug Administration. Biologics safety and availability communication. Expiration date extension for Anavip (Crotalidae Immune F(ab′)2 [Equine]): Lot B-8G-33 through July 31, 2021; Lot B-9B-33 through February 28, 2022; and Lot B-9E-35 through June 30, 2022. From FDA website. Accessed 2020 Apr 2. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/expiration-date-extension-anavip-crotalidae-immune-fab2-equine-lot-b-8g-33-through-july-31-2021-lot</p><h2>More about antivenin (crotalidae) polyvalent</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: antitoxins and antivenins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li data-more-config-id="list-data-resources-consumer">... +3 more</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Crotalidae Polyvalent Immune FAB (Ovine) &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Professional Patient Advice)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Venomous Snake Bite</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>